跳至主要内容
临床试验/CTIS2024-515260-31-00
CTIS2024-515260-31-00进行中(未招募)1 期

proMoting Effective Renoprotection in Cardiac sURgery patients by Inhibition of SGLT-2

Stichting Amsterdam UMC0 个研究点目标入组 784 人开始时间: 2024年6月11日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
784

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • > 18 years-old, Undergoing elective cardiac surgery with cardio-pulmonary bypass (CPB) or off-pump coronary artery bypass surgery (OPCAB)., Providing informed consent

排除标准

  • Current treatment with SGLT2 inhibitors, Reduced kidney function at baseline with eGFR < 20 ml/min at time of inclusion, Diabetes Mellitus Type 1, History of diabetic keto acidosis, Diabetes Mellitus Type 2 with BMI<25 for people with type 2 diabetes who are using multiple daily insulin injections (both short and long-acting insulin), Systolic blood pressure < 100 mmHg at time of inclusion, Emergency surgery, defined as in need of surgery for medical reasons < 7 days, i.e. S1- 4” according to the Amsterdam UMC classification, Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods, Known or suspected allergy to trial products or other drugs in the same class

研究者

相似试验

MERCURI-2 | 临床试验